Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $25.07, giving the company a market capitalization of 142.51B. It carries a P/E multiple of 14.88 and pays a dividend yield of 6.7%.
As of 2025-12-17, Pfizer(PFE) stock has fluctuated between $25.03 and $25.68. The current price stands at $25.07, placing the stock +0.2% above today's low and -2.4% off the high.
Pfizer(PFE) shares are trading with a volume of 61.26M, against a daily average of 53.06M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
PFE News
Pfizer's shares look attractive to investors willing to show patience. Stock investors have many options to choose among, of course. These include individual e...
The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE:PFE) Depo-Provera contraceptive injection, adding a warning abou...
Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's s...
Analyst ratings
57%
of 28 ratingsMore PFE News
Key Points Pfizer has a substantial 6.6% dividend yield but a payout ratio exceeding 100%. Eli Lilly has a payout ratio of roughly 30%, but its dividend yield...
Astellas Pharma (ALPMY) and Pfizer (PFE) announced topline results from an interim analysis of the Phase 3 EV-304 clinical trial for Padcev, a Nectin-4 directed...
Courtney Breen, an analyst from Bernstein, maintained the Hold rating on Pfizer. The associated price target remains the same with $30.00. Claim 50% Off TipRank...
Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached...
BofA analyst Jason Gerberry lowered the firm’s price target on Pfizer (PFE) to $27 from $28 and keeps a Neutral rating on the shares after the company “notably...
Pfizer Inc. (NYSE:PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share c...
Pfizer (PFE) stock was on the move Tuesday after the company received updated coverage from a top Wall Street analyst. Five-star Bank of America Securities anal...